H5N1 Insiders Speak Out

NSABB and Congress members voice their opinions about the new developments in the H5N1 research debate.

Written byCristina Luiggi
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Ron Fouchier, who leads one of the controversial H5N1 research projects (far left) with Bruce Alberts, Editor-in-Chief of Science and Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) at the American Society of Microbiologists biodefense meeting held on February 29. FLICKR, MICROBE WORLD

Since the US government asked the National Science Advisory Board for Biosecurity (NSABB) last week to reconsider revised manuscripts of controversial H5N1 research, which contain “new” and "clarified older data" not evaluated previously by the NSABB, several members of the security board, as well as a senior US congressman, have spoken out about the unfolding events.

Lynn Enquist, molecular biologist at Princeton University and one of the 23 voting members of the NSABB panel told ScienceInsider that the H5N1 experiments carried out independently by research teams at Erasmus Medical Center in Rotterdam, the Netherlands, and the University of Wisconsin, Madison, clearly fall under the classification of “experiments of concern” delineated by the highly influential 2003 National Academies report on biotechnology and terrorism.

“They not only ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies